BioProtect will present at ASTRO 2024Dec. 3, 2023
We look forward to welcoming you at Booth 2811, September 29 – October 2nd in Chicago, IL
BioProtect will present at AUA 2024Dec. 3, 2023
We look forward to welcoming you at Booth 123, May 3rd – 6th in San Antonio, TX
BioProtect will present at PTCOG-NA 2024Dec. 3, 2023
We look forward to welcoming you on April 5th – 9th in Boston, MA
BioProtect will present at ACRO 2024Dec. 3, 2023
We look forward to welcoming you on March 13th – 16th in Orlando, FL
BioProtect will present at IPCUM 2024Dec. 3, 2023
We look forward to welcoming you on February 11th – 14th in Vail, CO
BioProtect will present at Solaris 2024Dec. 3, 2023
We look forward to welcoming you on January 19th – 20th in Miami
BioProtect will present at SUO 2023Oct. 20, 2023
We look forward to welcoming you on November 28 – Dec 1 in Washington DC
BioProtect will present at ABS 2023Oct. 20, 2023
We look forward to welcoming you on November 9th – 11th in Seattle
BioProtect will present at LUGPA 2023Oct. 20, 2023
We look forward to welcoming you at booth #107, November 2nd – 4th in Orlando
BioProtect Secures $28M to Commercialize its Biodegradable Balloon for Rectal Protection During Prostate Cancer Radiation TherapySep. 27, 2023
TZUR IGAL, Israel – BioProtect Ltd, a private Med Tech company focused on providing innovative, biodegradable spacing solutions, announced today the successful close of a $28 million funding. The round was led by MVM Partners, with participation from current investors: Triventures, KB Investments, Peregrine Ventures, Almeda Ventures, and Consensus Business Group of Vincent Tchenguiz. Proceeds from this financing will support US commercialization of the BioProtect Balloon Implant System, which recently received FDA clearance for rectal protection during radiation therapy for prostate cancer.
“We believe that our balloon has the potential to revolutionize rectal protection from radiation toxicity during prostate cancer radiation therapy,” said BioProtect’s CEO, Itay Barnea. “To-date, our spacer has been successfully implanted in over 2,000 patients worldwide and has proven to be safe and effective. We appreciate the support of our new and existing investors who share our vision for the company, and are pleased to secure the resources to drive our penetration into the US market.”
“MVM aims to make best-in-class healthcare innovations more widely available to patients. We are impressed by the compelling benefits of BioProtect’s next generation spacer and are thrilled to support the US commercial launch of this technology”, said Kevin Cheng, a partner at MVM, who will be joining the company’s board of directors together with his colleague Stephen Reeders.
BioProtect will officially launch its balloon technology at the 2023 annual meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in San Diego, Oct. 1st – 4th.Read More
BioProtect will present at ASTRO 2023Sep. 5, 2023
We will be present at the Annual Meeting of the American Society for Radiation Oncology. We look forward to welcoming you at booth #1624, October 1-4, in San Diego Convention Center.
BioProtect LTD announces new GM and Chief Commercial Officer in the USSep. 4, 2023
TZUR IGAL, Israel, August 28, 2023 – Israeli medical devices manufacturer BioProtect Ltd. announced that it has nominated Ken Knudson as General Manager and Chief Commercial Officer effective August 1, 2023.
Knudson, who will lead BioProtect’s commercial activity, has a proven commercial track record in Urology and medical devices in general, including prior senior positions at Bard, Augmenix and Boston Scientific.
BioProtect receives FDA’s clearance for its biodegradable balloon for rectal protection during prostate cancer radiation therapyAugust 29, 2023
TZUR IGAL, Israel, August 28, 2023 – Israeli medical devices manufacturer BioProtect Ltd. announced today that their BioProtect Balloon ImplantTM System has been cleared by the FDA. The biodegradable balloon is a new generation spacer designed to provide optimal, consistent, and reproducible protection to the rectum during prostate cancer radiation therapy.
According to the American Cancer Society, prostate cancer is the second most common cancer among men in the United States, with 288,300 new cases diagnosed in 2023.
“We believe that our balloon has the potential to revolutionize rectal protection from toxicity during prostate cancer radiation therapy,” said Itay Barnea, CEO of BioProtect. “Not only does it provide better protection to healthy organs, it also supports dose escalation and hypofractionation, which are leading trends in prostate cancer radiation therapy.”
“The BioProtect Balloon offers me the opportunity to optimize treatment for almost all men with prostate cancer, even those with high-risk disease. The fact that it provides additional space with a pre-formed contour, the ability to adjust its position, and high visibility with all imaging modalities would make it the choice for my patients.” says Edward Soffen, MD, of Princeton Radiation Oncology.Read More
BioProtect will present at ASTRO 2022May 20, 2022
We will be present at the 64th Annual Meeting of the American Society for Radiation Oncology. We look forward to welcoming you at booth 1554, from to the 23rd to the 26th of October, at Henry B. González Convention Center, San Antonio, TX, USARead More
BioProtect will present at EMUC 2022
Join us while we will present our BioProtect Balloon Spacer at the European Multidisciplinary Congress on Urological Cancers in Budapest on 10-13 November 2022. Visit us at booth #4.
BioProtect will present at LUGPA 2022
Join us in Chicago November 10-12, 2022 for the LUGPA 2022 Annual Meeting. You are welcome to visit us at booth #26.
BioProtect presenting at ASCO GU 23
Join us in San Fransico February 16-18, 2023, for the ASCO GU 2023. You are welcome to visit us at booth #71.